The purpose of the study is to assess the efficacy of bortezomib, in association with
steroids, plasma exchange, and polyclonal intravenous immunoglobulins, in the treatment of
chronic antibody mediated rejection due to donor specific anti-HLA antibodies, in kidney
transplant recipients